Alumis (NASDAQ:ALMS) Releases Earnings Results, Beats Expectations By $0.05 EPS

Posted by on May 15th, 2026

Alumis (NASDAQ:ALMS – Get Free Report) released its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.05, FiscalAI reports. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $2.49 million.

Alumis Trading Down 0.9%

Alumis stock opened at $24.63 on Friday. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -8.05 and a beta of -0.31. The stock’s 50 day moving average is $24.56 and its 200-day moving average is $18.95. Alumis has a 12 month low of $2.76 and a 12 month high of $30.60.

Institutional Investors Weigh In On Alumis

Institutional investors have recently made changes to their positions in the stock. Virtus Investment Advisers LLC bought a new stake in shares of Alumis in the fourth quarter valued at approximately $226,000. Franklin Resources Inc. bought a new stake in shares of Alumis in the second quarter valued at approximately $209,000. Ieq Capital LLC boosted its stake in shares of Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after buying an additional 690 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Alumis in the third quarter valued at approximately $160,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Alumis by 134.1% in the fourth quarter. Russell Investments Group Ltd. now owns 15,029 shares of the company’s stock valued at $147,000 after buying an additional 8,610 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Stifel Nicolaus assumed coverage on Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price target on the stock. Raymond James Financial assumed coverage on Alumis in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $38.00 price target on shares of Alumis in a research report on Monday, March 30th. Morgan Stanley upped their target price on Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, March 20th. Finally, Loop Capital set a $37.00 target price on Alumis in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alumis presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.60.

Check Out Our Latest Report on ALMS

About Alumis

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Featured Articles

Earnings History for Alumis (NASDAQ:ALMS)

Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.